A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer-Reference-Cited by-同舟云学术

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Published:2018-01-16 Issue:4 Volume:7 Page:e1303584
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Schmitz-Winnenthal Friedrich H.¹,Hohmann Nicolas²^ORCID,Schmidt Thomas¹^ORCID,Podola Lilli³⁴,Friedrich Tobias⁵,Lubenau Heinz⁶,Springer Marco⁶,Wieckowski Sébastien⁷^ORCID,Breiner Klaus M.⁷,Mikus Gerd²^ORCID,Büchler Markus W.¹,Keller Anne-Valerie⁶,Koc Ruhan¹,Springfeld Christoph⁴,Knebel Phillip¹,Bucur Mariana³,Grenacher Lars⁸^ORCID,Haefeli Walter E.²,Beckhove Philipp³⁴

Affiliation:

1. Department of General, Abdominal and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany

2. Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany

3. Regensburg Center for Interventional Immunology (RCI), University Hospital Regensburg, Regensburg, Germany

4. Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany

5. Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany

6. VAXIMM GmbH, Mannheim, Germany

7. VAXIMM AG, Basel, Switzerland

8. Diagnostic Munich, Diagnostic Prevention and Imaging Center, Munich, Germany

Funder

VAXIMM AG

Publisher